Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

@article{Landgren2009RiskFF,
  title={Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.},
  author={O. Landgren and E. Gilbert and J. D. Rizzo and G. Soci{\'e} and P. Banks and K. Sobocinski and M. Horowitz and E. Jaffe and D. Kingma and L. Travis and M. Flowers and Paul J Martin and H. Deeg and R. Curtis},
  journal={Blood},
  year={2009},
  volume={113 20},
  pages={
          4992-5001
        }
}
We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA… Expand
Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
  • A. Fujimoto, N. Hiramoto, +16 authors R. Suzuki
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation
Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
Managing post-transplant lymphoproliferative disorder
T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.
...
1
2
3
4
5
...